M E Caplin
Overview
Explore the profile of M E Caplin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Desai K, Khan M, Toumpanakis C, Caplin M
Minerva Gastroenterol Dietol
. 2009 Nov;
55(4):425-43.
PMID: 19942827
Neuroendocrine tumors (NETs) are relatively rare neoplasms that often present as diagnostic dilemmas due to obscure or non-specific symptoms. The ability of carcinoid tumors to cause clinical symptoms by secretion...
12.
Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, et al.
Aliment Pharmacol Ther
. 2009 Jul;
30(7):733-40.
PMID: 19573169
Background: Octreotide LAR is an established treatment for malignant carcinoid syndrome. However, studies with large number of patients and long follow-up are lacking. Aim: To present long-terms results with octreotide...
13.
Srirajaskanthan R, Dancey G, Hackshaw A, Luong T, Caplin M, Meyer T
Endocr Relat Cancer
. 2009 Jun;
16(3):967-76.
PMID: 19502452
Angiogenesis is an essential process in the development and growth of tumours. There are a large number of angiogenic mediators including the angiopoietin (Ang) family and vascular endothelial growth factor,...
14.
Goulding J, Caplin M, Rustin M
Clin Exp Dermatol
. 2009 Mar;
34(3):439-41.
PMID: 19309383
No abstract available.
15.
Srirajaskanthan R, Watkins J, Marelli L, Khan K, Caplin M
Neuroendocrinology
. 2009 Mar;
89(3):308-14.
PMID: 19307732
Introduction: Somatostatin and dopamine receptors are both G-protein-coupled receptors. Somatostatin receptor (SSTR) expression in neuroendocrine tumours has been well characterised, and there is evidence of dopamine receptor expression in neuroendocrine...
16.
Srirajaskanthan R, Toumpanakis C, Meyer T, Caplin M
Aliment Pharmacol Ther
. 2009 Mar;
29(11):1143-54.
PMID: 19298583
Background: Gastroenteropancreatic neuroendocrine tumours (GEP NETs) are relatively uncommon tumours that occur anywhere within the gastrointestinal tract. The prevalence of GEP NETs is estimated to be 35 per 100 000...
17.
Srirajaskanthan R, Toumpanakis C, Karpathakis A, Marelli L, Quigley A, Dusmet M, et al.
Lung Cancer
. 2008 Dec;
65(1):68-73.
PMID: 19070398
Bronchial neuroendocrine tumours account for 1-2% of all lung cancers; they are thought to arise from the neuroendocrine cells located in the bronchial mucosa. The majority of the literature available...
18.
Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, et al.
Br J Cancer
. 2008 Jun;
99(1):72-7.
PMID: 18577995
Serum chromogranin A is the most useful general and prognostic tumour marker available for neuroendocrine tumour (NET) patients. The role of other tumour markers is less clear. In order to...
19.
Srirajaskanthan R, Toubanakis C, Dusmet M, Caplin M
Lung Cancer
. 2008 Mar;
60(1):4-13.
PMID: 18343528
Tumours of the thymus are uncommon and are generally regarded as being indolent. Whilst this is often true of thymomas; thymic adenocarcinoma and thymic neuroendocrine cancer can be aggressive and...
20.
Shah T, Hochhauser D, Frow R, Quaglia A, Dhillon A, Caplin M
J Neuroendocrinol
. 2006 Apr;
18(5):355-60.
PMID: 16629834
Epidermal growth factor receptor (EGFR) is expressed in many cancers and is associated with poor prognosis. EGFR activation pathways have been well characterised using tumour cell lines and are known...